These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 19593116)
21. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Mak KH; Bhatt DL; Shao M; Hankey GJ; Easton JD; Fox KA; Topol EJ Am Heart J; 2009 Apr; 157(4):658-65. PubMed ID: 19332192 [TBL] [Abstract][Full Text] [Related]
22. Metabolism of alpha 2-plasmin inhibitor ( alpha 2-PI) in a patient with congenital alpha 2-PI deficiency. Kamiya T; Takamatsu J; Koie K; Kohakura M Nihon Ketsueki Gakkai Zasshi; 1981 Dec; 44(7):1513-9. PubMed ID: 7342653 [No Abstract] [Full Text] [Related]
23. [Analysis of a single nucleotide deletion responsible for congenital plasmin inhibitor deficiency]. Nakahara M Rinsho Ketsueki; 2004 Jan; 45(1):1-5. PubMed ID: 14999928 [No Abstract] [Full Text] [Related]
24. Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina. Bayés-Genís A; Guindo J; Oliver A; Badimon L; Fiol M; Mateo J; Souto JC; Dominguez JM; Fontcuberta J; Bayés de Luna A Thromb Haemost; 1999 Jun; 81(6):865-8. PubMed ID: 10404758 [TBL] [Abstract][Full Text] [Related]
25. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism]. Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724 [TBL] [Abstract][Full Text] [Related]
26. Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. Miura O; Hirosawa S; Kato A; Aoki N J Clin Invest; 1989 May; 83(5):1598-604. PubMed ID: 2496145 [TBL] [Abstract][Full Text] [Related]
27. [Stress and ischemic heart disease]. Cas LD; Metra M; Nodari S; Nardi M; Giubbini R; Visioli O Cardiologia; 1993 Dec; 38(12 Suppl 1):415-25. PubMed ID: 8020044 [TBL] [Abstract][Full Text] [Related]
29. [Congenital plasmin inhibitor deficiencies: basic concepts and clinical applications]. Nakahara M; Koyama T Rinsho Ketsueki; 2003 Mar; 44(3):149-58. PubMed ID: 12722341 [No Abstract] [Full Text] [Related]
30. [Six case-control studies from the Osterbro-study (The Copenhagen City Heart Study). Angiotensinogen mutations and risk of myocardial and cerebral ischemia]. Sethi AA; Tybjaerg-Hansen A; Grønhold ML; Steffensen R; Schnohr P; Nordestgaard BG Lakartidningen; 2002 May; 99(21):2392-3. PubMed ID: 12090166 [No Abstract] [Full Text] [Related]
31. [Mechanisms of impaired secretion in patients with the deficiency of alpha 2-plasmin inhibitor]. Hirosawa S Rinsho Byori; 1997 Feb; Suppl 104():195-202. PubMed ID: 9128382 [No Abstract] [Full Text] [Related]
32. [Physiopathologic introduction to anesthesia and resuscitation of the vascular patient]. Coriat P J Mal Vasc; 1998 Feb; 23(1):35-40. PubMed ID: 9551351 [TBL] [Abstract][Full Text] [Related]
33. Alpha 2-plasmin inhibitor and its deficiency states. Saito H J Lab Clin Med; 1988 Dec; 112(6):671-8. PubMed ID: 3057093 [No Abstract] [Full Text] [Related]
34. Bleeding and thrombotic problems in a patient with alpha2 plasmin inhibitor deficiency. Hayward CP; Cinà CS; Staunton M; Jurriaans E J Thromb Haemost; 2005 Feb; 3(2):399-401. PubMed ID: 15670058 [No Abstract] [Full Text] [Related]
35. Alpha 2-antiplasmin: functional characterization and metabolism in a heterozygote deficient patient. Knot EA; ten Cate JW; Lamping RJ; Gie LK Thromb Haemost; 1986 Jun; 55(3):375-8. PubMed ID: 3750266 [TBL] [Abstract][Full Text] [Related]
36. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612 [TBL] [Abstract][Full Text] [Related]
37. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Oda H; Ohno M; Ohashi H Adv Perit Dial; 2000; 16():152-5. PubMed ID: 11045282 [TBL] [Abstract][Full Text] [Related]
38. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. O'Malley T; Ludlam CA; Riemermsa RA; Fox KA Eur Heart J; 2001 Jul; 22(14):1226-34. PubMed ID: 11440495 [TBL] [Abstract][Full Text] [Related]
39. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Villa P; Aznar J; Vaya A; España F; Ferrando F; Mira Y; Estellés A Thromb Haemost; 1999 Sep; 82(3):1011-4. PubMed ID: 10494755 [TBL] [Abstract][Full Text] [Related]
40. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ; Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]